URGN vs. ABCL, REPL, COLL, RCKT, EOLS, PHVS, AVBP, COGT, OCS, and BCYC
Should you be buying UroGen Pharma stock or one of its competitors? The main competitors of UroGen Pharma include AbCellera Biologics (ABCL), Replimune Group (REPL), Collegium Pharmaceutical (COLL), Rocket Pharmaceuticals (RCKT), Evolus (EOLS), Pharvaris (PHVS), ArriVent BioPharma (AVBP), Cogent Biosciences (COGT), Oculis (OCS), and Bicycle Therapeutics (BCYC). These companies are all part of the "pharmaceutical products" industry.
UroGen Pharma vs.
UroGen Pharma (NASDAQ:URGN) and AbCellera Biologics (NASDAQ:ABCL) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, community ranking, risk, dividends, analyst recommendations, profitability, institutional ownership, media sentiment and earnings.
91.3% of UroGen Pharma shares are held by institutional investors. Comparatively, 61.4% of AbCellera Biologics shares are held by institutional investors. 5.1% of UroGen Pharma shares are held by insiders. Comparatively, 28.0% of AbCellera Biologics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
In the previous week, AbCellera Biologics had 2 more articles in the media than UroGen Pharma. MarketBeat recorded 10 mentions for AbCellera Biologics and 8 mentions for UroGen Pharma. AbCellera Biologics' average media sentiment score of 0.58 beat UroGen Pharma's score of 0.19 indicating that AbCellera Biologics is being referred to more favorably in the news media.
UroGen Pharma received 316 more outperform votes than AbCellera Biologics when rated by MarketBeat users. However, 76.06% of users gave AbCellera Biologics an outperform vote while only 74.15% of users gave UroGen Pharma an outperform vote.
UroGen Pharma presently has a consensus price target of $39.20, indicating a potential upside of 288.89%. AbCellera Biologics has a consensus price target of $8.00, indicating a potential upside of 164.03%. Given UroGen Pharma's stronger consensus rating and higher possible upside, analysts plainly believe UroGen Pharma is more favorable than AbCellera Biologics.
UroGen Pharma has a beta of 1.08, indicating that its share price is 8% more volatile than the S&P 500. Comparatively, AbCellera Biologics has a beta of 0.42, indicating that its share price is 58% less volatile than the S&P 500.
UroGen Pharma has higher revenue and earnings than AbCellera Biologics. AbCellera Biologics is trading at a lower price-to-earnings ratio than UroGen Pharma, indicating that it is currently the more affordable of the two stocks.
UroGen Pharma has a net margin of -129.11% compared to AbCellera Biologics' net margin of -533.32%. UroGen Pharma's return on equity of 0.00% beat AbCellera Biologics' return on equity.
Summary
UroGen Pharma beats AbCellera Biologics on 12 of the 19 factors compared between the two stocks.
Get UroGen Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for URGN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
UroGen Pharma Competitors List
Related Companies and Tools
This page (NASDAQ:URGN) was last updated on 2/22/2025 by MarketBeat.com Staff
Free URGN Stock Alerts